Heart disease is still the leading cause of death globally, even after decades of advances in cholesterol-lowering drugs and blood-pressure control. That gap between what current treatments achieve and what patients still experience is sometimes called residual cardiovascular risk. A 2026 narrative review published in the journal Cells set out to examine one underappreciated piece of that puzzle: the chronic, low-grade inflammation that excess body fat produces, and whether a class of peptide-based therapies known as incretin-based therapies can meaningfully reduce it.
The review is not a simple story of weight loss equals lower risk. Instead, the authors worked through mechanistic studies, biomarker analyses, vascular imaging data, and large cardiovascular outcome trials to ask a more specific question. Do these therapies reduce atherosclerosis, the plaque-building process inside artery walls, through direct anti-inflammatory or vascular actions, or is most of the benefit simply explained by shedding weight and improving metabolic numbers? The answer, as the review makes clear, is still unsettled.
Obesity as an inflammatory state
Fat tissue does far more than store energy. When it expands beyond a healthy range, it becomes dysfunctional. The review describes how enlarged fat cells release a continuous stream of pro-inflammatory signals, drawing immune cells into the tissue and keeping them in a low-level activated state. This is not the acute inflammation that follows an infection. It is a quieter, persistent process that the authors describe as chronic low-grade inflammation.
This persistent inflammatory state links directly to the arteries. Oxidative stress rises, the lining of blood vessels becomes less responsive, and the conditions that allow fatty plaques to form inside artery walls, which is the hallmark of atherosclerosis, become more favorable. The review also points to ectopic fat accumulation, meaning fat deposited around organs like the liver and heart rather than under the skin, as a particularly potent driver of vascular injury. In this framing, obesity is not merely a risk factor for heart disease because of blood pressure or cholesterol. It is also an upstream source of inflammatory signaling that the standard risk-factor model may undercount.
Inflammation as a therapeutic target
Before examining incretin therapies specifically, the review surveys the broader evidence that inflammation is a modifiable pathway in cardiovascular disease. Several dedicated anti-inflammatory trials have tested whether directly suppressing specific inflammatory molecules reduces heart attacks and strokes in people at elevated risk. The results from those trials have been instructive but also cautionary.
The review notes that clinical benefit from anti-inflammatory strategies appears to depend heavily on which part of the inflammatory cascade is targeted, at what stage of disease, and in which type of patient. Some trials showed meaningful reductions in cardiovascular events. Others did not, even when biomarkers of inflammation fell. This reinforces the idea that inflammation in atherosclerosis is not a single lever but a complex network, and hitting the wrong node at the wrong time may not translate into protection.
Incretin-based therapies and the GLP-1 receptor
Incretin-based therapies work by mimicking or amplifying hormones that the gut naturally releases in response to food. The class reviewed here centers on glucagon-like peptide-1, or GLP-1, a peptide that acts on receptors found not just in the pancreas but in many other tissues, including the heart, blood vessels, and immune cells. Therapies that activate the GLP-1 receptor are the primary focus of the review, though the authors also consider newer agents that act on additional receptors at the same time.
Because GLP-1 receptors appear on vascular and immune cells, researchers have hypothesized that activating them might produce anti-inflammatory effects that go beyond whatever happens when a person loses weight. The review takes that hypothesis seriously and evaluates what the data actually show.
Biomarker and experimental findings
In mechanistic studies and biomarker analyses, the picture looks encouraging. The review reports that GLP-1 receptor agonists consistently reduce circulating markers of inflammation and oxidative stress in human studies. Levels of proteins associated with systemic inflammation tend to fall with treatment, and in experimental models, researchers have observed what look like direct anti-atherosclerotic effects, meaning changes in plaque composition or size that go beyond weight loss alone.
Animal and cell-culture models show GLP-1 receptor activation can reduce inflammatory signaling inside artery walls, limit the accumulation of certain immune cells in plaques, and improve the function of the endothelium, which is the thin layer of cells lining blood vessels. These findings have generated considerable excitement about a possible direct vascular mechanism.
What vascular imaging and outcome trials show
The gap between those experimental findings and firm human evidence is where the review becomes most cautious. Vascular imaging studies in people, which measure things like plaque volume or arterial wall thickness directly, have produced inconclusive results. Some studies show modest changes, others do not, and the review notes it is difficult to separate the effect of the therapy itself from the effect of the weight loss that accompanies it.
Large cardiovascular outcome trials tell a clearer story at the level of clinical events. Several GLP-1 receptor agonists have been shown in major trials to reduce the rate of heart attacks, strokes, and cardiovascular deaths in high-risk populations. One trial enrolled people with overweight or obesity who did not have diabetes, and still found a reduction in cardiovascular events with semaglutide, the generic peptide at the center of that research. This is a meaningful finding because it suggests the benefit is not entirely mediated through glucose control.
Yet even those trial results leave the mechanism question open. The review is explicit on this point: direct human evidence for receptor-mediated anti-inflammatory or anti-atherosclerotic effects remains limited. The relative contributions of weight loss, improved metabolic markers such as blood sugar, blood pressure, and lipids, and any additional receptor-specific mechanisms have not been cleanly separated in human data. The authors frame this as an important open question for future research.
What the review leaves researchers to investigate
The narrative review draws several threads together without fully resolving them, which is an honest reflection of where the science stands. The case that obesity-driven inflammation contributes to atherosclerotic risk is strong and supported by multiple lines of evidence. The case that incretin-based therapies modify that inflammatory pathway is plausible and backed by biomarker data and experimental models. The case that this anti-inflammatory action is a distinct, receptor-mediated mechanism on top of weight and metabolic benefits remains unproven in humans.
For researchers and clinicians following this field, the review points toward the kinds of studies still needed: trials designed specifically to measure vascular inflammation and plaque biology as primary endpoints, studies that control for weight loss to isolate receptor effects, and patient-selection work to identify who is most likely to benefit from the inflammatory pathway specifically. The authors also note that timing matters, echoing the lessons from earlier anti-inflammatory trials, and that the stage of atherosclerosis at which treatment begins may influence what kind of benefit is possible.
This is a field moving quickly. The cardiovascular outcome data are already reshaping clinical practice. The mechanistic story, however, is still being written, and the review makes clear that understanding exactly how these peptide therapies affect the artery wall in humans is one of the more important questions in cardiovascular medicine right now.
